Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-025650
Filing Date
2019-12-09
Accepted
2019-12-09 16:49:09
Documents
52
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0919_tffpharmaceuticals.htm 10-Q 479061
2 CERTIFICATION f10q0919ex31-1_tffpharma.htm EX-31.1 8917
3 CERTIFICATION f10q0919ex31-2_tffpharma.htm EX-31.2 9120
4 CERTIFICATION f10q0919ex32-1_tffpharma.htm EX-32.1 4260
  Complete submission text file 0001213900-19-025650.txt   2289668

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE tffp-20190930.xml EX-101.INS 313087
6 XBRL SCHEMA FILE tffp-20190930.xsd EX-101.SCH 33182
7 XBRL CALCULATION FILE tffp-20190930_cal.xml EX-101.CAL 28809
8 XBRL DEFINITION FILE tffp-20190930_def.xml EX-101.DEF 109541
9 XBRL LABEL FILE tffp-20190930_lab.xml EX-101.LAB 206901
10 XBRL PRESENTATION FILE tffp-20190930_pre.xml EX-101.PRE 170938
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 191275734
SIC: 2834 Pharmaceutical Preparations